Association of nesfatin-1 levels and bone remodeling markers in patients with rheumatoid arthritis

Aim. To evaluate the association of nesfatin-1 (NF-1) levels and bone remodeling markers in patients with rheumatoid arthritis (RA).

Materials and methods. 110 patients (105 women and 5 men) with RA, classified by ACR/EULAR 2010 criteria were enrolled in our study. All patients undergone complete clinical and laboratory examination. NF-1 serum levels were determined using a commercial test-systems (RayBio® Nesfatin Enzyme Immunoassay [EIA] Kit). Statistical analysis was performed using a software package Statistica 12.0. The results were considered statistically significant at p < 0.050.

Results. Significant positive correlation was determined between serum NF-1 levels and Intact N-Terminal Propeptide of Type 1 Procollagen (P1NP) levels (r = 0.218; p = 0.022). Serum NF-1 levels were not associated with bone mineral density in lumbar spine and femur. Serum NF-1 levels didn't correlate with body composition indices and Beta-CrossLaps levels. Patients with osteoporosis (n = 53) and osteoporotic fractures (n = 25) had statistically significant higher levels of NF-1 (Z = –2.060; p = 0.040 и Z = –2.370; p = 0.017 respectively). However, serum NF-1 levels didn’t correlate with cumulative dose of glucocorticoids (ρ = 0.090; p = 0.368) and the duration of glucocorticoids intake (ρ = 0.070; p = 0.462).

Conclusions. In our study, we determined the significant positive correlation between NF-1 and P1NP levels, supposingly due to NF-1 possible effect on the osteoblasts differentiation and function. Patients with osteoporosis and osteoporotic fractures had higher median blood serum levels of NF-1.

1. Li R., Wu Q., Zhao Y., et al. The Novel Pro-Osteogenic Activity of NUCB 2. PLoS ONE. 2013; 8(4): e61619. DOI: 10.1371/journal.pone.0061619.

2. Scotece M., Conde J., Abella V., et al. NUCB 2/nesfatin-1: a new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties, an in vitro study. J. Orthop. Res. 2014; 32 (5): P. 653–60. DOI: 10.1002/jor.22585.

3. Ayada C., Toru U., Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015; 19: 4–10.

4. Tang C. H., Fu X. J., Xu X. L., et al. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012; 36: 39–45. DOI: 10.1016/j.peptides.2012.04.014.

5. Oh-I.S., Shimizu H., Satoh T., et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443709–712. DOI: 10.1038/nature05162.

6. Mirzaeia K., Hossein-nezhadb A, Keshavarzd S. A. Association of nesfatin-1 level with body composition, dietary intake and resting metabolic rate in obese and morbid obese subjects. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015; 9 (4): 292–98. DOI: 10.1016/j.dsx.2014.04.010.

7. Papichev E. V., Zavodovsky B. V., Sivordova L. E., et al. Clinical and laboratory markers of rheumatic cachexia in rheumatoid arthritis. Russian Medical Journal. 2021; 7: 3–6.

8. Korshunov N. I., Kurygin A. G., Rechkina E. V., et al. Rheumatoid arthritis as a psychosomatic disease. Scientific and Practical Rheumatology. 2015; 53 (5): 469–71. DOI: 10.14412/1995–4484–2015–469–471.

9. St-Pierre Martin J., Shimizu H., et al. Association between nesfatin-1 levels and metabolic improvements in severely obese patients who underwent biliopancreatic derivation with duodenal switch. Peptides. 2016; 86: 6–12. DOI: 10.1016/j.peptides.2016.09.014.

10. Kvlividze T. Z., Zavodovsky B. V., Akhverdyan Yu.R., et al. Serum nesfatin-1 as a marker of systemic inflammation in rheumatoid arthritis. Klin Lab Diagn. 2019; 64 (1): 53–56. DOI: 10.18821/0869–2084–2019–64–1–53–56.

11. Durward G., Non-Pugh C., Ogunremi L., et al. Detection of risk of falling and hip fracture in women referred for bone densitometry. Lancet. 1999; 354: 220–221. DOI: 10.1016/S0140–6736(99)01871–1.

12. Leveille S., Jones R., Kiely D., et al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA. 2009; 302: 2214–2221. DOI: 10.1001/jama.2009.1738.

13. Shostak N. A., Muradyants A. A. Rheumatoid arthritis and osteoporosis. Russian Medical Journal. 2004; 5: 287. https://www.rmj.ru/archive/chelovek_i_lekarstvo

14. Petersson U., Somogyi E., Reinholt F. P. Nucleobindin is produced by bone cells and secreted into the osteoid, with a potential role as a modulator of matrix maturation. Bone. 2004; 34 (6): 949–60. DOI: 10.1016/j.bone.2004.01.019.

15. Li R., Wu Q., Zhao Y., et al. The Novel Pro-Osteogenic Activity of NUCB 21–83. PLoS One. 2013; 8 (4): e61619. DOI: 10.1371/journal.pone.0061619.

16. Brosch S., Redlich K., Pietschmann P. Pathogenesis of osteoporosis in rheumatoid arthritis. Acta medica Austriaca. 2003; 301: 1–5. DOI: 10.1046/j.1563-2571.2002.02047.x.

17. Popkova T. V., Novikova D. S., Nasonov E. L. Cardiovascular disease in rheumatoid arthritis: new data. Scientific and Practical Rheumatology. 2016; 54 (2): 122–28. DOI: 10.14412/1995–4484–2016–122–128.

18. Robinson C., Tsang L., Solomon A., et al. Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis. Peptides. 2018; 102: 31–7. DOI: 10.1016/j.peptides.2018.02.002.

19. Dai H., Li X., He T., et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2013; 46: 167–71. DOI: 10.1016/j.peptides.2013.06.006.

20. Ding S., Qu W., Dang S., et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med. Sci. Monit. 2015; 21: 987–91. DOI: 10.12659/MSM.892611.

21. Schalla M., Stengel A. Current Understanding of the Role of Nesfatin-1. J Endocr Soc. 2018; 2 (10): 1188–206. DOI: 10.1210/js.2018–00246.